Predictive factors of vascular complications after transcatheter aortic valve implantation in patients treated with a default percutaneous strategy.

BACKGROUND Percutaneous approach techniques with closure device after transcatheter aortic valve implantation (TAVI) have diminished vascular complications (VC). In this retrospective study, we will report incidence and angiographic factors predisposing to major VC in patients undergoing TAVI using Prostar® XL closure device as a default strategy. METHODS Consecutive patients, who underwent TAVI transfemorally using Prostar® XL, were evaluated for the incidence of VC according to VARC criteria. Using arterial angiography, the femoral-iliac arterial tortuosity was adjusted for large arterial diameters and expressed as the ratio total tortuosity/arterial diameter (TT/AD). Arterial calcification, the combination of angulation and atheromatosis at the puncture site and ideal puncture were evaluated too. In all patients, 30 days of follow-up was available. RESULTS Eighty-four patients (80.2 ± 5.86 years, 39 males [46.4%]), who were consecutively treated with the transfemoral approach, were evaluated. In patients with major VC (17/84 [20.23%]) comparing to those without, arterial calcification (11 [64.7%] vs. 8 [11.9%], P < 0.01) and the TT/AD (30.2 ± 11.25 vs. 22.06 ± 8.64, P < 0.01) were independent predictors. Ideal puncture was achieved more frequently among patients without VC comparing to those with major (94.1% vs. 70.6%, P = 0.01). Blood transfusions (1.48 ± 0.37 vs. 2.45 ± 0.59, P = 0.023) were more frequent among patients with major VC. Finally, minimum creatinin clearance after TAVI predicted all-cause 30-day mortality (P = 0.021). CONCLUSIONS Major VC after TAVI with the use of Prostar closure device can be predicted by arterial calcification at the puncture site and TT/AD ratio. Minimum creatinin clearance after TAVI predicted 30-day mortality.

[1]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, The Journal of thoracic and cardiovascular surgery.

[2]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.

[3]  Scott T Reeves,et al.  Guidelines for performing ultrasound guided vascular cannulation: recommendations of the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[4]  A. Kirtane,et al.  Clinical outcomes using a new crossover balloon occlusion technique for percutaneous closure after transfemoral aortic valve implantation. , 2011, JACC. Cardiovascular interventions.

[5]  M. Morice,et al.  Transfemoral aortic valve implantation new criteria to predict vascular complications. , 2011, JACC. Cardiovascular interventions.

[6]  P. Serruys,et al.  Frequency, determinants, and prognostic effects of acute kidney injury and red blood cell transfusion in patients undergoing transcatheter aortic valve implantation , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  G. Finet,et al.  Percutaneous femoral artery access with Prostar device for innovative mitral and aortic interventions. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  P. Serruys,et al.  One year follow-up of the multi-centre European PARTNER transcatheter heart valve study , 2010, European heart journal.

[9]  P. Serruys,et al.  Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium , 2010, European heart journal.

[10]  Enrico Ferrari,et al.  Transcatheter aortic valve implantation (TAVI): state of the art techniques and future perspectives. , 2010, Swiss medical weekly.

[11]  P. Lin,et al.  Access site management with vascular closure devices for percutaneous transarterial procedures. , 2010, Journal of vascular surgery.

[12]  R. Tölg,et al.  Anatomic and procedural predictors of paravalvular aortic regurgitation after implantation of the Medtronic CoreValve bioprosthesis. , 2010, Journal of the American College of Cardiology.

[13]  C. Stefanadis,et al.  "Bail out" procedures for malpositioning of aortic valve prosthesis (CoreValve). , 2010, International journal of cardiology.

[14]  C. Stefanadis,et al.  Transcatheter aortic valve implantation, patient selection process and procedure: two centres' experience of the intervention without general anaesthesia. , 2010, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[15]  S. Pocock,et al.  Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.

[16]  Thomas Walther,et al.  Thirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry: A European Registry of Transcatheter Aortic Valve Implantation Using the Edwards SAPIEN Valve , 2010, Circulation.

[17]  M. Kern,et al.  Real-time ultrasound guidance facilitates femoral arterial access and reduces vascular complications: FAUST (Femoral Arterial Access With Ultrasound Trial). , 2010, JACC. Cardiovascular interventions.

[18]  Christodoulos Stefanadis,et al.  CoreValve aortic bioprosthesis: repositioning techniques. , 2010, JACC. Cardiovascular interventions.

[19]  O. Alfieri,et al.  A new technique for vascular access management in transcatheter aortic valve implantation , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[20]  Fabian Nietlispach,et al.  Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. , 2010, Journal of the American College of Cardiology.

[21]  D. Tsetis Endovascular Treatment of Complications of Femoral Arterial Access , 2010, CardioVascular and Interventional Radiology.

[22]  Philippe Pibarot,et al.  Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement , 2009, European heart journal.

[23]  J. Fajadet,et al.  Thirty-day outcome and vascular complications after transarterial aortic valve implantation using both Edwards Sapien and Medtronic CoreValve bioprostheses in a mixed population. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[24]  P. Serruys,et al.  Vascular complications with transcatheter aortic valve implantation using the 18 Fr Medtronic CoreValve System: the Rotterdam experience. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  Y. Castier,et al.  Vascular complications of transfemoral aortic valve implantation with the Edwards SAPIEN prosthesis: incidence and impact on outcome. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[26]  R. Lange,et al.  Survival after transapical and transfemoral aortic valve implantation: talking about two different patient populations. , 2009, The Journal of thoracic and cardiovascular surgery.

[27]  A. Cribier,et al.  Aorto-iliac angiography as a screening tool in selecting patients for transfemoral aortic valve implantation with the Edwards SAPIEN bioprosthesis. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[28]  Susheel Kodali,et al.  ranscatheter Aortic Valve Implantation eview of the Nature , Management , and Avoidance of Procedural Complications , 2022 .

[29]  R. Erbel,et al.  Vascular Access Site Complications after Percutaneous Transfemoral Aortic Valve Implantation , 2009, Herz Kardiovaskuläre Erkrankungen.

[30]  J. Leipsic,et al.  CT of the ilio-femoral arteries using direct aortic contrast injection: proof of feasibility in patients screened towards percutaneous aortic valve replacement. , 2009, Swiss medical weekly.

[31]  Fabian Nietlispach,et al.  Transcatheter Aortic Valve Implantation: Impact on Clinical and Valve-Related Outcomes , 2009, Circulation.

[32]  P. Serruys,et al.  Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[33]  T. Vassiliades,et al.  The clinical development of percutaneous heart valve technology: a position statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society for Cardiovascular Angiography and Interventions (SCAI). , 2005, The Annals of thoracic surgery.

[34]  C. White,et al.  Percutaneous management of access site complications , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[35]  D. Baim,et al.  Suture-mediated closure of the femoral access site after cardiac catheterization: results of the suture to ambulate aNd discharge (STAND I and STAND II) trials. , 2000, The American journal of cardiology.

[36]  S. Money,et al.  Complications associated with percutaneous closure devices. , 1999, American journal of surgery.

[37]  U. Gerckens,et al.  Management of arterial puncture site after catheterization procedures: evaluating a suture-mediated closure device. , 1999, The American journal of cardiology.

[38]  E. Diethrich,et al.  Closure of Large Percutaneous Access Sites Using the Prostar XL Percutaneous Vascular Surgery Device , 1999, Journal of endovascular surgery : the official journal of the International Society for Endovascular Surgery.

[39]  J. Webb,et al.  Initial experience using Prostar: a new device for percutaneous suture-mediated closure of arterial puncture sites. , 1996, Catheterization and cardiovascular diagnosis.

[40]  F. Veith,et al.  Management of arterial injuries produced by percutaneous femoral procedures. , 1993, Surgery.